Last reviewed · How we verify
duvie
At a glance
| Generic name | duvie |
|---|---|
| Sponsor | Pusan National University Hospital |
| Target | Peroxisome proliferator-activated receptor alpha, Peroxisome proliferator-activated receptor gamma |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Diabetes mellitus type 2
Common side effects
Key clinical trials
- Pharmacokinetics and Safety of M107 Orally Disintegrating Tablet in Healthy Adults (PHASE1)
- Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic of CKD-501, D745, and D150 for Healthy Subjects in Fed State. (PHASE1)
- Comparison of Dapagliflozin, Lobeglitazone, and Its Combination in Efficacy and Safety (PHASE4)
- Glucose-Lowering Effects and Safety of Adding 0.25 or 0.5 mg Duvie (PHASE4)
- Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy (PHASE4)
- Retrospective Study to Evaluate the Safety of Duvie in Korean Patients With Type 2 Diabetes Mellitus
- Comparison of Lobeglitazone With Pioglitazone as Initial Triple Therapy for Diabetes Management (PHASE4)
- Therapeutic Efficacy of Triple Combination in Drug-naïve Korean Type 2 Diabetic Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |